Contrasting Medical Marijuana (MJNA) and The Competition

Medical Marijuana (OTCMKTS:MJNA) is one of 226 publicly-traded companies in the “Drug Manufacturers—Specialty & Generic” industry, but how does it weigh in compared to its peers? We will compare Medical Marijuana to related companies based on the strength of its risk, earnings, valuation, analyst recommendations, institutional ownership, profitability and dividends.

Analyst Ratings

This is a breakdown of current ratings for Medical Marijuana and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medical Marijuana	0	0	0	0	N/A
Medical Marijuana Competitors	152	793	1458	16	2.55

As a group, “Drug Manufacturers—Specialty & Generic” companies have a potential upside of 16.10%. Given Medical Marijuana’s peers higher possible upside, analysts clearly believe Medical Marijuana has less favorable growth aspects than its peers.

Earnings and Valuation

This table compares Medical Marijuana and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Medical Marijuana	N/A	N/A	-0.68
Medical Marijuana Competitors	$720.29 million	-$26.70 million	144.03

Medical Marijuana’s peers have higher revenue, but lower earnings than Medical Marijuana. Medical Marijuana is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

0.0% of Medical Marijuana shares are owned by institutional investors. Comparatively, 19.7% of shares of all “Drug Manufacturers—Specialty & Generic” companies are owned by institutional investors. 27.7% of shares of all “Drug Manufacturers—Specialty & Generic” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Medical Marijuana and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Medical Marijuana	N/A	N/A	N/A
Medical Marijuana Competitors	-56.96%	-66.18%	-9.84%

Summary

Medical Marijuana peers beat Medical Marijuana on 5 of the 8 factors compared.

Medical Marijuana Company Profile

Medical Marijuana, Inc., an investment holding company, operates in the cannabinoid-based nutraceutical industry. It focuses on the development, sale, and distribution of hemp oil that contains naturally occurring cannabinoids, including cannabidiol (CBD) and other products containing CBD-rich hemp oil; treatment of pain and other medical disorders with the application of chewing gum-based cannabis/cannabinoid medical products; and nonpsychoactive cannabidiol products. The company is also involved in the research and development of new therapeutic agents that are designed to reduce oxidative stress and act as immuno-modulators and neuroprotectants; dietary supplements, skin care products, and prescription-based hemp oil under the Kannaway and HempMeds brands; and proprietary testing, genetics, labeling and packaging, tracking, and production and standardization methods for the medicinal cannabinoid industry. In addition, it offers RSHO oil for the treatment of various illnesses and conditions; and plant-based, non-GMO pet products for health and wellness, play and wear, and environmentally-friendly supplies. Medical Marijuana, Inc. was incorporated in 2005 and is based in San Diego, California.